(NASDAQ: ONCY) Oncolytics Biotech's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.42%.
Oncolytics Biotech's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ONCY's revenue for 2027 to be $6,003,110,228, with the lowest ONCY revenue forecast at $6,003,110,228, and the highest ONCY revenue forecast at $6,003,110,228. On average, 1 Wall Street analysts forecast ONCY's revenue for 2028 to be $23,650,749,918, with the lowest ONCY revenue forecast at $23,650,749,918, and the highest ONCY revenue forecast at $23,650,749,918.
In 2029, ONCY is forecast to generate $39,437,121,362 in revenue, with the lowest revenue forecast at $39,437,121,362 and the highest revenue forecast at $39,437,121,362.